<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amblyopia in children: Management and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amblyopia in children: Management and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Amblyopia in children: Management and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David K Coats, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evelyn A Paysse, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Olitsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H130340"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amblyopia is a functional reduction in visual acuity caused by abnormal visual development early in life. It is the most common cause of pediatric visual impairment, occurring in an estimated 1 to 4 percent of children. Early detection and treatment of amblyopia facilitates earlier treatment, which improves visual outcomes. This is the basis for screening preschool-age children for vision problems and amblyopia (<a class="graphic graphic_table graphicRef62277 graphicRef104862" href="/d/graphic/62277.html" rel="external">table 1A-B</a>). (See  <a class="medical medical_review" href="/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children", section on 'Vision screening'</a>.)</p><p>The management and outcome of amblyopia in children is reviewed here. The definition, classification, and diagnosis of amblyopia are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation"</a>.)</p><p>The management of strabismus and refractive errors in children are also discussed separately. (See  <a class="medical medical_review" href="/d/html/6269.html" rel="external">"Evaluation and management of strabismus in children"</a> and  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children"</a>.)</p><p class="headingAnchor" id="H132421"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Amblyopia is classified by the underlying cause of the visual disturbance [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Strabismic amblyopia — Caused by abnormal alignment of the eyes (see  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Strabismic amblyopia'</a> and  <a class="medical medical_review" href="/d/html/6269.html" rel="external">"Evaluation and management of strabismus in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Refractive amblyopia — Caused by unequal focus between eyes (see  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Refractive amblyopia'</a> and  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deprivation amblyopia — Caused by structural abnormalities of the eye that obscure incoming images (eg, cataract) (see  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Deprivation amblyopia'</a> and  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children"</a>)</p><p></p><p class="headingAnchor" id="H178705317"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Stepwise treatment of amblyopia includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Eliminating any visual obstructions (eg, cataracts, ptosis), if necessary (see  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children", section on 'Management'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Correcting refractive errors (see  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children", section on 'Optical correction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encouraging use of the amblyopic eye (eg, patching, pharmacologic penalization) (see <a class="local">'Patching'</a> below and <a class="local">'Pharmacologic penalization (atropine)'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring for recurrence and treating it if it occurs (see <a class="local">'Recurrence'</a> below)</p><p></p><p>Children with amblyopia should be managed by an eye specialist who is appropriately trained and experienced in treating children [<a href="#rid2">2</a>]. The goal of treatment is to achieve maximal potential visual acuity.</p><p class="headingAnchor" id="H178705337"><span class="h2">Timing</span><span class="headingEndMark"> — </span>Treatment should be initiated as early as possible since clinical trials have demonstrated improved long-term outcomes when treatment is started at young age (ie, &lt;5 years) [<a href="#rid3">3</a>]. Amblyopia is most responsive to treatment when initiated before age 7 years, and the upper age limit for optimal therapy is considered to be in the range of 9 to 10 years [<a href="#rid4">4-9</a>]. Although it is optimal to begin therapy in early childhood, we agree with the American Academy of Ophthalmology's recommendation to attempt treatment in all children with previously untreated amblyopia, regardless of age [<a href="#rid2">2</a>]. Approximately half of older children (7 to 17 years) with previously untreated amblyopia respond to treatment [<a href="#rid10">10</a>]. (See <a class="local">'Children seven years and older'</a> below.)</p><p class="headingAnchor" id="H178705511"><span class="h2">Vision correction</span><span class="headingEndMark"> — </span>The cause of visual deprivation (eg, cataracts, ptosis) must be eliminated in children with deprivation amblyopia before the use of the amblyopic eye can be encouraged. Similarly, significant refractive error must be corrected with glasses and/or contact lenses in children with amblyopia due to a refractive error. Patching the better-seeing eye in the treatment of amblyopia is of little benefit if the amblyopic eye remains unable to focus clearly because of uncorrected refractive error. (See  <a class="medical medical_review" href="/d/html/6260.html" rel="external">"Refractive errors in children"</a>.)</p><p>In children with mild to moderate refractive amblyopia (ie, visual acuity 20/40 to 20/80), refractive correction alone may be sufficient treatment in up to a third of patients [<a href="#rid11">11-14</a>]. Such patients may be treated initially with glasses alone and are followed up in three to four months. The patient can continue to be observed if the vision continues to improve with glasses alone. If amblyopia persists, patching or pharmacologic penalization is started. (See <a class="local">'Patching'</a> below and <a class="local">'Pharmacologic penalization (atropine)'</a> below.)</p><p class="headingAnchor" id="H178705613"><span class="h2">Use of amblyopic eye</span><span class="headingEndMark"> — </span>In children with strabismic amblyopia and those with severe (ie, visual acuity of 20/100 or worse) refractive amblyopia, correction of refractive errors alone is generally not sufficient treatment. The child must be encouraged to use the amblyopic eye. This is accomplished by discouraging use of the better-seeing eye with a patch (occlusion) or cycloplegic eye drops (penalization) [<a href="#rid15">15-18</a>]. A 2014 systematic review that included three randomized trials concluded that the combination of refractive correction plus occlusion/penalization was more effective than refractive correction alone for the treatment of strabismic amblyopia [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H178705695"><span class="h3">Patching</span><span class="headingEndMark"> — </span>Occlusion therapy involves patching the eye with better vision. Close-range visual activities (eg, arts and crafts activities, board games, reading, writing) during patching are commonly used to encourage use of the amblyopic eye; however, the benefit of near activities is unproven [<a href="#rid19">19,20</a>].</p><p>The prescribed duration of patching varies from two hours to all waking hours per day, depending upon the age of the child (younger children generally require less occlusion than do older children), the cause and severity of the amblyopia (severe amblyopia usually requires more intensive patching than does mild to moderate amblyopia), and the preferences of the treating specialist and parents. For most patients with mild to moderate amblyopia, treatment can be initiated with two hours of daily patching [<a href="#rid2">2</a>]. If no improvement is achieved at the first or second follow-up visit, the patching dose is increased to four to six hours per day or more [<a href="#rid21">21,22</a>]. (See <a class="local">'Residual amblyopia'</a> below.)</p><p>In a randomized controlled trial comparing two hours of daily patching with glasses alone (if needed) in 180 children with strabismic and anisometropic amblyopia, visual acuity (measured with the Snellen chart) improved to a greater degree after five weeks of patching (average improvement of 1.1 lines) compared with glasses alone (average improvement of 0.5 lines) [<a href="#rid23">23</a>].</p><p>In a retrospective study of 246 children with strabismic (68 percent) and anisometropic (32 percent) amblyopia treated with occlusion therapy, successful outcomes (linear acuity 6/12 or better) were achieved in 85 percent of the children with strabismic amblyopia and 100 percent of those with anisometropia [<a href="#rid24">24</a>]. Factors correlated with unsuccessful outcome included poor visual acuity at the start of treatment, more than one diopter of anisometropia, hypermetropia of more than three diopters, and poor or only fair compliance with the treatment plan [<a href="#rid24">24</a>]. Neither age at presentation nor age at start of treatment correlated with outcome in this study. However, other studies have shown better results with early referral [<a href="#rid7">7,25</a>].</p><p>Clinical trials evaluating different durations of patching (eg, 6 versus 24 hours, 2 versus 6 hours) in children with severe and moderate amblyopia have found similar improvements regardless of the prescribed duration of patching [<a href="#rid14">14,23,26-28</a>]. One reason for this may be that patches are worn for fewer hours than they are prescribed. In a study in which adherence with prescribed patching was objectively monitored, the patch was actually worn 4.2 and 6.2 hours per day in children for whom it was prescribed for 6 and 12 hours, respectively [<a href="#rid29">29</a>].</p><p>The major disadvantage to occlusion therapy is compliance. Many children resist wearing the patch. They may remove it or peel it back enough to allow peeking. Both of these measures may render treatment less effective or completely ineffective. Adherence to the treatment plan is more likely in younger children and is a critical factor in outcome [<a href="#rid24">24,30,31</a>]. In addition, clear communication, including written instructions for parents and pictures for children, improves compliance with patching [<a href="#rid32">32-34</a>]. (See  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Information for patients'</a>.)</p><p>Strategies to encourage compliance include allowing the child to play a favorite video game or watch television only when the patch is worn. Digital applications for smartphones, tablets, and other devices have been developed that can provide binocular training as a compliment or alternative to patching. Data are limited on the efficacy of these devices [<a href="#rid35">35-38</a>]. In addition, the games available on these platforms may not hold the child's attention for a sufficient amount of time. Other strategies to improve compliance have been explored (eg, supervised inpatient occlusion treatment and suturing or gluing the occluder in place), but these are generally impractical [<a href="#rid39">39-41</a>]. </p><p>Children undergoing patching therapy are at risk for developing occlusion amblyopia in the fellow eye, and it is therefore important to monitor visual acuity in both eyes at each visit [<a href="#rid42">42</a>]. Based upon the results of the Amblyopia Treatment Studies demonstrating that fewer hours of prescribed patching were as effective as the prescription of full-time patching [<a href="#rid26">26-28</a>], many ophthalmologists prescribe fewer hours per day of patching, and as a result, occlusion amblyopia is much less frequent than it was previously. Fear of occlusion amblyopia may cause some parents to limit patching or avoid it altogether; however, it is important to recognize that it occurs rarely and is almost always reversible. Occlusion amblyopia is not necessarily a reason to curtail or discontinue treatment unless the drop in visual acuity worsens on subsequent visits.</p><p class="headingAnchor" id="H178706120"><span class="h3">Pharmacologic penalization (atropine)</span><span class="headingEndMark"> — </span>Visual blurring, through the use of a cycloplegic agent in the sound eye, temporarily handicaps the sound eye, thus encouraging use of the amblyopic eye. Pharmacologic penalization is not effective for patients with myopia.</p><p><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> is the cycloplegic agent used most commonly, but other agents (eg, <a class="drug drug_pediatric" data-topicid="13352" href="/d/drug information/13352.html" rel="external">homatropine</a>, <a class="drug drug_pediatric" data-topicid="16045" href="/d/drug information/16045.html" rel="external">scopolamine</a>) are used by some ophthalmologists. In our practice, when pharmacologic penalization is prescribed, we typically use atropine (1% ophthalmic solution, one drop to the sound eye once a day on weekends or daily) for children ≥2 years and <a class="drug drug_pediatric" data-topicid="13189" href="/d/drug information/13189.html" rel="external">cyclopentolate</a> (1% ophthalmic solution, one drop to the sound eye once a day on weekends or daily) for children &lt;2 years. However, we generally prefer patching over pharmacologic penalization in children &lt;2 years because the risk of systemic side effects with cycloplegic agents (as described below) is likely higher in this age group. (See <a class="local">'Choice of treatment'</a> below.)</p><p><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> causes pupillary dilation, temporary paralysis of the ciliary body, and loss of the ability to accommodate. The loss of ability to accommodate reduces the ability of the sound eye to focus, thereby providing the amblyopic eye with a competitive advantage and encouraging its use.</p><p>Side effects of <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> include light sensitivity, conjunctival irritation, eye pain, fever, flushing, headache, dry mouth, rapid heart rate, and allergic reaction. Other cycloplegic agents, all of which are anticholinergic agents, have similar side effects. In a large clinical trial, side effects were reported in 26 percent of patients treated with atropine drops [<a href="#rid43">43</a>]. The most common adverse effects were light sensitivity (18 percent) and conjunctival irritation (4 percent). Clinical trials of atropine drops have generally not included children &lt;3 years, and systemic side effects may be more likely in this age group.</p><p><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> penalization appears to be as effective as patching [<a href="#rid3">3,43-46</a>]. In a large multicenter randomized trial comparing atropine with patching (for a minimum of six hours per day) in 419 young children with moderate amblyopia, visual acuity in the amblyopic eye (measured with the Snellen chart) improved after six months of treatment by three lines in similar proportions of both groups (79 percent of the patching group and 74 percent of the atropine group) [<a href="#rid43">43</a>]. In follow-up studies, no differences were observed in visual acuity of amblyopic and fellow eyes at 10 and 15 years of age [<a href="#rid3">3,47</a>]. Visual acuity in the amblyopic eye was maintained at 20/25 or better in 60 percent of patients at age 15 years [<a href="#rid3">3</a>].</p><p>Different schedules of <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> are used. In children with mild to moderate amblyopia (visual acuity 20/80 or better), weekend atropine is equally effective compared with daily use [<a href="#rid48">48</a>].</p><p>Blurring of the sound eye can also be accomplished with optical penalization, although this is usually less effective than <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> due to the ability of the child to simply remove the spectacles or contact lens. It is almost always used in conjunction with pharmacologic penalization. (See <a class="local">'Ineffective and unproven therapies'</a> below.)</p><p class="headingAnchor" id="H178706335"><span class="h3">Choice of treatment</span><span class="headingEndMark"> — </span>In choosing the initial treatment for a child with amblyopia, the clinician should consider the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Likelihood of compliance with prescribed therapy – Adherence to prescribed treatment is better with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> compared with patching. In the clinical trial described previously, patient adherence to the prescribed treatment was rated as "excellent" in 78 percent in the atropine group compared with 49 percent in the patching group [<a href="#rid43">43</a>]. Adherence with patching is more likely in younger children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential side effects – Side effects (including light sensitivity, conjunctival irritation, eye pain, fever, flushing, headache, dry mouth, rapid heart rate, and allergic reactions) occur in one-quarter of children treated with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> drops [<a href="#rid43">43</a>]. The most common side effect is light sensitivity. Reverse amblyopia (ie, reduced visual acuity in the previously nonamblyopic eye) can occur with either patching or atropine, but it occurs more frequently with atropine. Skin irritation is common with patching, but it is generally mild.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age of the patient – In children &lt;2 years old, we prefer patching over <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> because the risk of systemic side effects with atropine is likely higher in this age group. When pharmacologic penalization is used in children &lt;2 years, we typically use <a class="drug drug_pediatric" data-topicid="13189" href="/d/drug information/13189.html" rel="external">cyclopentolate</a> (1% ophthalmic solution, one drop to the sound eye daily) rather than atropine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence/type of refractive error – <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> is not effective for patients with myopia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severity of amblyopia – Patching is generally preferred over <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> for patients with severe amblyopia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preferences of the parent/patient – Patching is generally preferred by parents of young children (&lt;2 years). For older children, studies have found that <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> drops had better acceptance by parents and children, particularly with regards to perceptions of social stigma and ability to comply with the treatment [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential interference of pharmacologic blurring agents on driving and performance of other activities – This is particularly important in older children and adolescents. (See <a class="local">'Children seven years and older'</a> below.)</p><p></p><p>For most patients, patching and <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> are equally effective in treating amblyopia. Patching is often prescribed as the initial treatment, and it is generally preferred by parents of young children. Atropine, despite its occasional side effects, is also a reasonable first choice, particularly in patients expected to have poor compliance with patching.</p><p>After one or two follow-up intervals, it may be necessary to change treatment modality, particularly if any of the following occur:</p><p class="bulletIndent1"><span class="glyph">●</span>Adherence with the prescribed treatment is poor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically significant side effects develop (eg, severe skin irritation with patching or severe photosensitivity with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Visual acuity has not improved. Increasing treatment intensity (eg, patching for six rather than two hours; daily rather than weekend <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a>) is another option for patients that have a poor response to initial therapy. (See <a class="local">'Residual amblyopia'</a> below.)</p><p></p><p class="headingAnchor" id="H178706452"><span class="h3">Children seven years and older</span><span class="headingEndMark"> — </span>Visual outcomes for children with amblyopia are generally better when treatment is initiated in early childhood. However, there is emerging evidence that patching and <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> can be effective treatments in older children and adolescents, particularly if they have not previously been treated [<a href="#rid2">2,10</a>]. This evidence has challenged the previously held notion that the "sensitive period" (ie, the age at which successful treatment of amblyopia can be achieved) has an upper age limit of approximately seven years [<a href="#rid4">4,5,8,9</a>].</p><p>A multicenter randomized trial evaluated the effectiveness of treatment of amblyopia in 507 amblyopic children aged 7 to 17 years randomly assigned to receive optical correction alone or optical correction and additional treatment (consisting of two to six hours of daily patching for all children in the treatment group, plus <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> drops for children aged 7 to 12 years) [<a href="#rid10">10</a>]. Approximately one-quarter of the patients responded (ie, ≥2 lines improvement in visual acuity in the amblyopic eye) with visual correction alone. Among children aged 7 to 12 years, the response rate was greater in the treatment than the control group (53 versus 25 percent). The response rate was similar in both groups among children aged 13 to 17 years; however, among the treated children in this age group, the response rate was greater in those who had never been treated for amblyopia than in those who had (47 versus 20 percent). Most patients, including those who responded to treatment, had residual deficits in visual acuity. For this reason, many older children will reasonably decline treatment, unless the parents and child are unusually motivated and/or the amblyopia has not been previously treated. In addition, the rate of recurrence after treatment in late childhood is unknown.</p><p>Although these data provide encouraging evidence that it is possible to effectively treat amblyopia in late childhood, they should not de-emphasize the need to identify and treat children with amblyopia as early as possible. The difficulties inherent in treating older children (eg, lack of adherence to the treatment plan, potential interference of pharmacologic blurring agents on driving and performance of other activities) highlight the importance of early identification and treatment [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H178706610"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>Treatment is continued until visual acuity is normal or near normal or until maximal improvement has been achieved, which is usually established when there is no further improvement observed between two or three follow-up intervals. In a study evaluating the time course of amblyopia improvement, the median duration of patching required to reach maximal improvement was 20.2 weeks [<a href="#rid22">22</a>]. A duration of six months or more of treatment is usually needed. More than two years of treatment is required in 30 to 40 percent of cases [<a href="#rid6">6</a>].</p><p>Once visual acuity has been maximally improved, maintenance therapy may be advised for another 4 to 12 months to prevent recurrence. In children treated with more intensive patching regimens, patching is typically tapered (eg, reduced to two hours a day) during this maintenance therapy period. Some experts recommend maintenance therapy be continued until the child is seven to eight years old, the age at which the visual system is essentially mature and recurrent amblyopia is unlikely to recur [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H178706658"><span class="h3">Residual amblyopia</span><span class="headingEndMark"> — </span>Patients who have residual amblyopia after initial treatment with patching or <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> may benefit from increasing treatment intensity (eg, patching for six rather than two hours; daily atropine use rather than weekend only) or changing to a different treatment modality.</p><p>Two randomized trials have evaluated treatment of residual amblyopia:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>After patching</strong> – For patients with residual amblyopia after treatment with patching, there is some evidence that increasing the prescribed patching time may provide further improvement in visual acuity.</p><p></p><p class="bulletIndent1">In a multicenter trial, 169 children (3 to &lt;8 years) with residual amblyopia after ≥12 weeks of patching for two hours per day were randomly assigned to two versus six hours of daily patching [<a href="#rid21">21</a>]. After 10 weeks, six hours of daily patching resulted in greater improvements in visual acuity (1.2 versus 0.5 lines), and more children assigned to six hours of patching had improvement in visual acuity ≥2 lines (40 versus 18 percent).</p><p></p><p class="bulletIndent1">In cases of particularly refractory amblyopia, <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> is sometimes added to full-time patching to reduce the vision in the good eye when the child removes the patch. This makes the vision disparity between the amblyopic and normal eye less apparent to the child and sometimes permits better compliance with patching.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After </strong><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> – For patients with residual amblyopia after treatment with atropine, there may be a small benefit to augmenting atropine therapy with optical penalization (also called a plano lens).</p><p></p><p class="bulletIndent1">In a randomized trial, 73 children (3 to &lt;8 years) with residual amblyopia after ≥12 weeks of <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> treatment were randomly assigned to continuing weekend atropine alone or with optical penalization (ie, wearing a plano lens over the fellow eye in addition to continuing atropine) [<a href="#rid53">53</a>]. After 10 weeks, amblyopic eye visual acuity had improved an average of 1.1 lines with the plano lens and 0.6 lines with atropine only (difference between the two groups, adjusted for baseline visual acuity, was 0.5 lines; 95% CI -0.1 to +1.2). While the results from this study are promising, the relatively small number of children treated and the lack of a statistically significant difference between the two groups precludes drawing firm conclusions as to the benefit of this therapy. A larger study is needed to more precisely estimate the treatment effect.</p><p></p><p class="headingAnchor" id="H178706740"><span class="h3">Recurrence</span><span class="headingEndMark"> — </span>Approximately one-quarter of patients treated for amblyopia experience recurrence within the first year after stopping therapy [<a href="#rid6">6,28,54,55</a>]. When amblyopia recurs after stopping therapy, restarting the previously prescribed treatment will usually restore visual acuity to its previous level [<a href="#rid2">2,54</a>].</p><p>In patients treated with moderately intense patching (six to eight hours per day), the risk of recurrence is reduced if patching is tapered to two hours a day prior to stopping therapy rather than stopping abruptly [<a href="#rid55">55,56</a>]. In addition, for patients prescribed glasses and/or contact lenses to correct refractive errors, it is imperative that they continue to wear glasses or contact lenses after stopping treatment with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> or patching.</p><p class="headingAnchor" id="H178706860"><span class="h2">Refractive surgery</span><span class="headingEndMark"> — </span>There is a small subset of children with amblyopia or amblyogenic levels of refractive error who can be treated with refractive surgery procedures (photorefractive keratectomy, laser in situ keratomileusis, refractive lens exchange, phakic intraocular lenses) with reasonable and sometimes excellent visual outcomes [<a href="#rid57">57-60</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe anisometropia with amblyopia</strong> – In children with extremely high refractive error in one eye only, correction with glasses causes a condition called aniseikonia (difference in image size) such that the eyes cannot function visually together. Secondarily, the children can experience asthenopia (eye fatigue, headache) from this correction and most refuse to wear the glasses. Contact lenses are another option, but they are difficult to insert in uncooperative children, loss is frequent, and they are costly. The consequence of this intolerance/noncompliance is severe amblyopia [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isoametropic amblyopia</strong> – The children with bilateral severe ametropia who refuse to wear glasses typically have neurobehavioral problems, such as autism, genetic disorders, or cerebral palsy, or craniofacial abnormalities such as microtia, that make wearing glasses impractical. These children live in a world of blur, and everything visual is only perceived when it is a few inches from their face. Thus, visual stimuli can be frightening, and the children typically are combative and difficult to manage. One author has coined the term "visual autism" for this condition [<a href="#rid58">58</a>].</p><p></p><p class="headingAnchor" id="H178706968"><span class="h2">Protection for the sound eye</span><span class="headingEndMark"> — </span>Patients with residual unilateral vision impairment (ie, best corrected visual acuity of 20/50 or worse) after treatment for amblyopia should wear protective eyewear in order to prevent traumatic vision loss in the sound eye, even if they do not require optical correction [<a href="#rid2">2</a>]. Loss of vision in the nonamblyopic eye can result in permanent bilateral visual impairment or blindness [<a href="#rid61">61,62</a>]. In a population-based study of 370 individuals with unilateral amblyopia, the projected lifetime risk of bilateral vision loss was 1.2 to 3.3 percent [<a href="#rid63">63</a>]. In 16 percent of patients, vision loss in the nonamblyopic eye was a result of orbital or ocular trauma.</p><p class="headingAnchor" id="H178707028"><span class="h2">Ineffective and unproven therapies</span><span class="headingEndMark"> — </span>A number of other therapies have been studied in children with amblyopia; however, based on the available evidence, they are <strong>not</strong> routinely recommended. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optical penalization</strong> – Optical penalization involves altering the spectacles to produce blur in the better-seeing eye (also called a plano lens). A major disadvantage to isolated optical penalization is that children can easily avoid the undesired blur by removing or looking over their glasses. Optical penalization can be used alone or, more typically, in combination with pharmacologic penalization. A randomized clinical trial comparing isolated optical penalization with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> therapy found atropine to be superior [<a href="#rid64">64</a>]. A subsequent clinical trial that evaluated the use of optical penalization in combination with atropine failed to demonstrate any advantage over atropine alone [<a href="#rid65">65</a>]. There may be a small benefit to augmenting atropine therapy with optical penalization in children with residual amblyopia after treatment with atropine; however, the evidence is insufficient to draw firm conclusions [<a href="#rid53">53</a>]. (See <a class="local">'Residual amblyopia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic treatments</strong> – Systemic treatments have been attempted with limited success. Levodopa has been reported to improve visual acuity in both normal and amblyopic eyes; however, the improvement regresses after discontinuation of the drug [<a href="#rid66">66,67</a>]. A randomized placebo-controlled trial found that in older children (ages 7 to 12 years) with residual amblyopia after patching therapy, treatment with levodopa and continued patching did not result in improved visual acuity compared with placebo and patching [<a href="#rid68">68</a>]. Initial studies of citicoline (cytidine-5'-diphosphocholine) in amblyopic children were promising; however, definitive studies on this agent are lacking [<a href="#rid69">69,70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vision training</strong> – Novel binocular interactive video games have shown some promise in initial trials and are the subject of ongoing research [<a href="#rid71">71-74</a>]. Therapies such as eye movement exercises, vision training, passive occlusion, and methods designed to stimulate or suppress vision using flashing lights or rapidly rotating patterns have not been well investigated and have few data to support their use [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acupuncture</strong> – Acupuncture is commonly used for the treatment of amblyopia in China and East Asia. A randomized trial comparing acupuncture with patching in older children with anisometropic amblyopia found similar improvement in visual acuity with both therapies [<a href="#rid75">75</a>]. In another randomized crossover trial, young children with anisometropic amblyopia were found to have greater improvement in visual acuity when treated with acupuncture and glasses compared with glasses alone [<a href="#rid76">76</a>]. These trials were single-center studies with relatively small sample sizes, and the results have not been reproduced. In addition, the cost associated with acupuncture treatment is considerably greater than that of patching [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H178707428"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>After stopping treatment, children with amblyopia require regular ongoing follow-up with a pediatric eye care specialist. The period of greatest risk for recurrence is within the first 13 weeks of stopping treatment; the risk is low beyond two years [<a href="#rid54">54,78</a>]. (See <a class="local">'Recurrence'</a> above.)</p><p>Most ophthalmologists follow-up patients with amblyopia three to four months after stopping active therapy to check for deterioration. If there is none, the follow-up interval usually is increased to six months and then increased further if the examination remains stable. Younger patients and those who have deterioration in their vision require longer follow-up.</p><p class="headingAnchor" id="H178707475"><span class="h1">OUTCOME</span></p><p class="headingAnchor" id="H178707482"><span class="h2">Visual function</span><span class="headingEndMark"> — </span>Visual outcome for most children treated with patching or <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> before age seven years is good, although many children do not attain normal vision. Factors that are associated with a good prognosis include younger age (ie, &lt;5 years) at the start of treatment, better baseline visual acuity in the amblyopic eye, and good compliance with prescribed treatment.</p><p>Long-term visual outcomes in children treated for amblyopia before age seven years were demonstrated in a follow-up study of 147 children who participated in a multicenter trial comparing patching and <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> [<a href="#rid3">3,43</a>]. At 15 years of age, the following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The mean amblyopic eye acuity was approximately 20/25.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>60 percent of amblyopic eyes had a visual acuity of 20/25 or better, and 33 percent were 20/20 or better.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mean difference in visual acuity between eyes was 2.1 lines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;5 years at the time of enrollment was associated with better visual acuity outcome (mean visual acuity approximately 20/25 versus 20/32).</p><p></p><p>Amblyopia may affect binocularity and fine depth perception. Fusion and stereopsis, the central formation of a three-dimensional image from the images perceived by each eye, are dependent upon receiving clear images from each eye simultaneously [<a href="#rid79">79</a>]. Whether impaired stereoacuity can be avoided or reversed by amblyopia treatment is not yet established [<a href="#rid61">61</a>]. Even if normal visual acuity is achieved with treatment, patients with a history of amblyopia may have deficits in perception of images in the real world, poor motor performance, and poor eye-hand coordination [<a href="#rid80">80-83</a>].</p><p>Patients with residual unilateral vision impairment after treatment for amblyopia are at risk for permanent bilateral visual impairment or blindness should vision loss occur in the nonamblyopic eye. (See <a class="local">'Protection for the sound eye'</a> above.)</p><p class="headingAnchor" id="H178707619"><span class="h2">Psychosocial consequences</span><span class="headingEndMark"> — </span>It is unclear whether amblyopia has any long-term psychosocial consequences. In a survey of 25 patients with a history of amblyopia, approximately half responded that amblyopia interfered with their schooling, work, or lifestyle, and approximately 40 percent responded that it affected their ability to play sports or influenced their job choices [<a href="#rid84">84</a>]. However, in a population-based study of 3318 young children, of whom 71 (2.1 percent) had amblyopia, general health-related quality of life (as reported by parents) was similar in children with and without amblyopia [<a href="#rid85">85</a>]. In a study evaluating long-term psychosocial outcomes in patients with amblyopia using data from the 1958 British birth cohort, no differences were found between people with and without amblyopia in educational outcomes, employment, participation in social activities, injuries, general or mental health, or mortality [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H130879"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16726.html" rel="external">"Patient education: Crossed eyes and lazy eye (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H130903"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Amblyopia is a functional reduction in visual acuity caused by abnormal visual development early in life and is classified based upon associated clinical findings. (See <a class="local">'Introduction'</a> above and <a class="local">'Terminology'</a> above and  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Etiology and classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of early treatment</strong> – Early detection and treatment of amblyopia improves visual outcomes. This is the basis for screening preschool-age children for vision problems and amblyopia (<a class="graphic graphic_table graphicRef62277 graphicRef104862" href="/d/graphic/62277.html" rel="external">table 1A-B</a>). Amblyopia is most responsive to treatment when initiated before age seven years. However, all children with amblyopia should undergo treatment, regardless of their age. (See <a class="local">'Timing'</a> above and  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Children with amblyopia should be managed by an eye specialist who is appropriately trained and experienced in treating children. Treatment of amblyopia requires elimination of any visual obstruction and correction of refractive errors (if present), followed by encouragement of use of the amblyopic eye (through patching or <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> drops). (See <a class="local">'Vision correction'</a> above and <a class="local">'Use of amblyopic eye'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of treatment</strong> – Patching and <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> are equally effective in treating mild to moderate amblyopia. Patching is often prescribed as the initial treatment, and it is generally preferred by parents of young children. Atropine, despite its occasional side effects, is also a reasonable first choice, particularly in patients expected to have poor compliance with patching. (See <a class="local">'Choice of treatment'</a> above and <a class="local">'Patching'</a> above and <a class="local">'Pharmacologic penalization (atropine)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited role of refractive surgery</strong> – In rare cases of amblyopia associated with severe unilateral (anisometropic) or bilateral (isoametropic) refractive error, refractive surgery may be a helpful adjunct therapy. (See <a class="local">'Refractive surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – After stopping treatment, children with amblyopia require regular ongoing follow-up with a pediatric eye care specialist. Approximately one-quarter of patients treated for amblyopia experience recurrence within the first year after stopping therapy. Recurrence is most likely to occur within 13 weeks after stopping treatment. (See <a class="local">'Recurrence'</a> above and <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Visual outcome for most children treated with patching or <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> before age seven years is good, although many children do not attain normal vision. Factors that are associated with a good prognosis include younger age (ie, &lt;5 years) at start of treatment, better baseline visual acuity in the amblyopic eye, and good compliance with prescribed treatment. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protection of the sound eye</strong> – Patients with residual unilateral vision impairment after treatment for amblyopia are at risk for permanent bilateral visual impairment or blindness should vision loss occur in the nonamblyopic eye. Protective eyewear should be worn at all times in these patients, even if they do not require optical correction. (See <a class="local">'Protection for the sound eye'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Day S. Normal and abnormal visual development. In: Pediatric Ophthalmology, Taylor D (Ed), Blackwell Scientific Publications, Cambridge, MA 1990. p.7.</li><li class="breakAll">American Academy of Ophtalmology Pediatric Ophthalmology/Strabismus Panel. Preferred Practice Pattern Guidelines. Amblyopia. American Academy of Ophthalmology, San Francisco, CA: American Academy of Ophthalmology; 2012. Available at: http://www.aao.org/preferred-practice-pattern/amblyopia-ppp--september-2012 (Accessed on August 05, 2015).</li><li><a class="nounderline abstract_t">Repka MX, Kraker RT, Holmes JM, et al. Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial. JAMA Ophthalmol 2014; 132:799.</a></li><li><a class="nounderline abstract_t">Epelbaum M, Milleret C, Buisseret P, Dufier JL. The sensitive period for strabismic amblyopia in humans. Ophthalmology 1993; 100:323.</a></li><li><a class="nounderline abstract_t">Simons K, Preslan M. Natural history of amblyopia untreated owing to lack of compliance. Br J Ophthalmol 1999; 83:582.</a></li><li><a class="nounderline abstract_t">Repka MX, Wallace DK, Beck RW, et al. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2005; 123:149.</a></li><li><a class="nounderline abstract_t">Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia treatment in children. Arch Ophthalmol 2011; 129:1451.</a></li><li><a class="nounderline abstract_t">Flynn JT, Schiffman J, Feuer W, Corona A. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc 1998; 96:431.</a></li><li><a class="nounderline abstract_t">Assaf AA. The sensitive period: transfer of fixation after occlusion for strabismic amblyopia. Br J Ophthalmol 1982; 66:64.</a></li><li><a class="nounderline abstract_t">Scheiman MM, Hertle RW, Beck RW, et al. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005; 123:437.</a></li><li><a class="nounderline abstract_t">Cotter SA, Pediatric Eye Disease Investigator Group, Edwards AR, et al. Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology 2006; 113:895.</a></li><li><a class="nounderline abstract_t">Stewart CE, Moseley MJ, Fielder AR, et al. Refractive adaptation in amblyopia: quantification of effect and implications for practice. Br J Ophthalmol 2004; 88:1552.</a></li><li><a class="nounderline abstract_t">Writing Committee for the Pediatric Eye Disease Investigator Group, Cotter SA, Foster NC, et al. Optical treatment of strabismic and combined strabismic-anisometropic amblyopia. Ophthalmology 2012; 119:150.</a></li><li><a class="nounderline abstract_t">Taylor K, Powell C, Hatt SR, Stewart C. Interventions for unilateral and bilateral refractive amblyopia. Cochrane Database Syst Rev 2012; :CD005137.</a></li><li><a class="nounderline abstract_t">Cleary M. Efficacy of occlusion for strabismic amblyopia: can an optimal duration be identified? Br J Ophthalmol 2000; 84:572.</a></li><li><a class="nounderline abstract_t">Mazow ML, Chuang A, Vital MC, Prager T. 1999 Costenbader Lecture. Outcome study in amblyopia: treatment and practice pattern variations. J AAPOS 2000; 4:1.</a></li><li><a class="nounderline abstract_t">France TD, France LW. Optical penalization can improve vision after occlusion treatment. J AAPOS 1999; 3:341.</a></li><li><a class="nounderline abstract_t">Simons K, Gotzler KC, Vitale S. Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997; 104:2156.</a></li><li><a class="nounderline abstract_t">Taylor K, Elliott S. Interventions for strabismic amblyopia. Cochrane Database Syst Rev 2014; :CD006461.</a></li><li><a class="nounderline abstract_t">Holmes JM, Edwards AR, Beck RW, et al. A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia. J AAPOS 2005; 9:129.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Wallace DK, Lazar EL, et al. A randomized trial of increasing patching for amblyopia. Ophthalmology 2013; 120:2270.</a></li><li><a class="nounderline abstract_t">Wallace DK, Lazar EL, Crouch ER 3rd, et al. Time course and predictors of amblyopia improvement with 2 hours of daily patching. JAMA Ophthalmol 2015; 133:606.</a></li><li><a class="nounderline abstract_t">Wallace DK, Pediatric Eye Disease Investigator Group, Edwards AR, et al. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology 2006; 113:904.</a></li><li><a class="nounderline abstract_t">Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus 1999; 36:19.</a></li><li><a class="nounderline abstract_t">Flynn JT, Woodruff G, Thompson JR, et al. The therapy of amblyopia: an analysis comparing the results of amblyopia therapy utilizing two pooled data sets. Trans Am Ophthalmol Soc 1999; 97:373.</a></li><li><a class="nounderline abstract_t">Holmes JM, Kraker RT, Beck RW, et al. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology 2003; 110:2075.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with patching in children: experience of the amblyopia treatment study. Am J Ophthalmol 2003; 136:620.</a></li><li><a class="nounderline abstract_t">Repka MX, Beck RW, Holmes JM, et al. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol 2003; 121:603.</a></li><li><a class="nounderline abstract_t">Stewart CE, Stephens DA, Fielder AR, et al. Objectively monitored patching regimens for treatment of amblyopia: randomised trial. BMJ 2007; 335:707.</a></li><li><a class="nounderline abstract_t">Lithander J, Sjöstrand J. Anisometropic and strabismic amblyopia in the age group 2 years and above: a prospective study of the results of treatment. Br J Ophthalmol 1991; 75:111.</a></li><li><a class="nounderline abstract_t">Oliver M, Neumann R, Chaimovitch Y, et al. Compliance and results of treatment for amblyopia in children more than 8 years old. Am J Ophthalmol 1986; 102:340.</a></li><li><a class="nounderline abstract_t">Newsham D. A randomised controlled trial of written information: the effect on parental non-concordance with occlusion therapy. Br J Ophthalmol 2002; 86:787.</a></li><li><a class="nounderline abstract_t">Tjiam AM, Holtslag G, Vukovic E, et al. An educational cartoon accelerates amblyopia therapy and improves compliance, especially among children of immigrants. Ophthalmology 2012; 119:2393.</a></li><li><a class="nounderline abstract_t">Dean SE, Povey RC, Reeves J. Assessing interventions to increase compliance to patching treatment in children with amblyopia: a systematic review and meta-analysis. Br J Ophthalmol 2016; 100:159.</a></li><li><a class="nounderline abstract_t">Tailor V, Ludden S, Bossi M, et al. Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years. Cochrane Database Syst Rev 2022; 2:CD011347.</a></li><li><a class="nounderline abstract_t">Roy S, Saxena R, Dhiman R, et al. Comparison of Dichoptic Therapy Versus Occlusion Therapy in Children With Anisometropic Amblyopia: A Prospective Randomized Study. J Pediatr Ophthalmol Strabismus 2023; 60:210.</a></li><li><a class="nounderline abstract_t">Wygnanski-Jaffe T, Kushner BJ, Moshkovitz A, et al. An Eye-Tracking-Based Dichoptic Home Treatment for Amblyopia: A Multicenter Randomized Clinical Trial. Ophthalmology 2023; 130:274.</a></li><li><a class="nounderline abstract_t">Kelly KR, Jost RM, Dao L, et al. Binocular iPad Game vs Patching for Treatment of Amblyopia in Children: A Randomized Clinical Trial. JAMA Ophthalmol 2016; 134:1402.</a></li><li><a class="nounderline abstract_t">Dorey SE, Adams GG, Lee JP, Sloper JJ. Intensive occlusion therapy for amblyopia. Br J Ophthalmol 2001; 85:310.</a></li><li><a class="nounderline abstract_t">Arnold RW, Armitage MD, Limstrom SA. Sutured protective occluder for severe amblyopia. Arch Ophthalmol 2008; 126:891.</a></li><li><a class="nounderline abstract_t">Rubab S, French D, Levin AV. Glued patches for children resistant to amblyopia occlusion therapy. Arch Ophthalmol 2008; 126:133.</a></li><li><a class="nounderline abstract_t">Simon JW, Parks MM, Price EC. Severe visual loss resulting from occlusion therapy for amblyopia. J Pediatr Ophthalmol Strabismus 1987; 24:244.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group.. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2002; 120:268.</a></li><li><a class="nounderline abstract_t">Foley-Nolan A, McCann A, O'Keefe M. Atropine penalisation versus occlusion as the primary treatment for amblyopia. Br J Ophthalmol 1997; 81:54.</a></li><li><a class="nounderline abstract_t">Scheiman MM, Hertle RW, Kraker RT, et al. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Arch Ophthalmol 2008; 126:1634.</a></li><li><a class="nounderline abstract_t">Li T, Shotton K. Conventional occlusion versus pharmacologic penalization for amblyopia. Cochrane Database Syst Rev 2009; :CD006460.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, et al. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Arch Ophthalmol 2008; 126:1039.</a></li><li><a class="nounderline abstract_t">Repka MX, Cotter SA, Beck RW, et al. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004; 111:2076.</a></li><li><a class="nounderline abstract_t">Holmes JM, Strauber S, Quinn GE, et al. Further validation of the Amblyopia Treatment Index parental questionnaire. J AAPOS 2008; 12:581.</a></li><li><a class="nounderline abstract_t">Felius J, Chandler DL, Holmes JM, et al. Evaluating the burden of amblyopia treatment from the parent and child's perspective. J AAPOS 2010; 14:389.</a></li><li><a class="nounderline abstract_t">Hunter DG. Treatment of amblyopia in older children. Arch Ophthalmol 2005; 123:557.</a></li><li><a class="nounderline abstract_t">Walsh LA, Hahn EK, Laroche GR. Stability of visual acuity after the cessation of amblyopia treatment: review of the literature. Am Orthopt J 2007; 57:89.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Wallace DK, Lazar EL, et al. A randomized trial of adding a plano lens to atropine for amblyopia. J AAPOS 2015; 19:42.</a></li><li><a class="nounderline abstract_t">De Weger C, Van Den Brom HJ, Lindeboom R. Termination of amblyopia treatment: when to stop follow-up visits and risk factors for recurrence. J Pediatr Ophthalmol Strabismus 2010; 47:338.</a></li><li><a class="nounderline abstract_t">Holmes JM, Melia M, Bradfield YS, et al. Factors associated with recurrence of amblyopia on cessation of patching. Ophthalmology 2007; 114:1427.</a></li><li><a class="nounderline abstract_t">Walsh LA, Hahn EK, LaRoche GR. The method of treatment cessation and recurrence rate of amblyopia. Strabismus 2009; 17:107.</a></li><li><a class="nounderline abstract_t">Paysse EA, Coats DK, Hussein MA, et al. Long-term outcomes of photorefractive keratectomy for anisometropic amblyopia in children. Ophthalmology 2006; 113:169.</a></li><li><a class="nounderline abstract_t">Tychsen L, Hoekel J. Refractive surgery for high bilateral myopia in children with neurobehavioral disorders: 2. Laser-assisted subepithelial keratectomy (LASEK). J AAPOS 2006; 10:364.</a></li><li><a class="nounderline abstract_t">Yin ZQ, Wang H, Yu T, et al. Facilitation of amblyopia management by laser in situ keratomileusis in high anisometropic hyperopic and myopic children. J AAPOS 2007; 11:571.</a></li><li><a class="nounderline abstract_t">Astle WF, Rahmat J, Ingram AD, Huang PT. Laser-assisted subepithelial keratectomy for anisometropic amblyopia in children: outcomes at 1 year. J Cataract Refract Surg 2007; 33:2028.</a></li><li><a class="nounderline abstract_t">Solebo AL, Cumberland PM, Rahi JS. Whole-population vision screening in children aged 4-5 years to detect amblyopia. Lancet 2015; 385:2308.</a></li><li><a class="nounderline abstract_t">Woodruff G. Amblyopia: could we do better? BMJ 1995; 310:1153.</a></li><li><a class="nounderline abstract_t">Rahi J, Logan S, Timms C, et al. Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study. Lancet 2002; 360:597.</a></li><li><a class="nounderline abstract_t">Tejedor J, Ogallar C. Comparative efficacy of penalization methods in moderate to mild amblyopia. Am J Ophthalmol 2008; 145:562.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group. Pharmacological plus optical penalization treatment for amblyopia: results of a randomized trial. Arch Ophthalmol 2009; 127:22.</a></li><li><a class="nounderline abstract_t">Brandies R, Yehuda S. The possible role of retinal dopaminergic system in visual performance. Neurosci Biobehav Rev 2008; 32:611.</a></li><li><a class="nounderline abstract_t">Yang X, Luo D, Liao M, et al. Efficacy and tolerance of levodopa to treat amblyopia: a systematic review and meta-analysis. Eur J Ophthalmol 2012; :0.</a></li><li><a class="nounderline abstract_t">Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, et al. A randomized trial of levodopa as treatment for residual amblyopia in older children. Ophthalmology 2015; 122:874.</a></li><li><a class="nounderline abstract_t">Campos EC, Schiavi C, Benedetti P, et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 1995; 233:307.</a></li><li><a class="nounderline abstract_t">Campos EC, Bolzani R, Schiavi C, et al. Cytidin-5'-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 1996-1997; 93:247.</a></li><li><a class="nounderline abstract_t">Birch EE, Li SL, Jost RM, et al. Binocular iPad treatment for amblyopia in preschool children. J AAPOS 2015; 19:6.</a></li><li><a class="nounderline abstract_t">Li SL, Jost RM, Morale SE, et al. Binocular iPad treatment of amblyopia for lasting improvement of visual acuity. JAMA Ophthalmol 2015; 133:479.</a></li><li><a class="nounderline abstract_t">Li SL, Jost RM, Morale SE, et al. A binocular iPad treatment for amblyopic children. Eye (Lond) 2014; 28:1246.</a></li><li class="breakAll">Study of Binocular Computer Activities for Treatment of Amblyopia (ATS18), available at https://www.clinicaltrials.gov/ct2/show/NCT02200211 (Accessed on September 22, 2015).</li><li><a class="nounderline abstract_t">Zhao J, Lam DS, Chen LJ, et al. Randomized controlled trial of patching vs acupuncture for anisometropic amblyopia in children aged 7 to 12 years. Arch Ophthalmol 2010; 128:1510.</a></li><li><a class="nounderline abstract_t">Lam DS, Zhao J, Chen LJ, et al. Adjunctive effect of acupuncture to refractive correction on anisometropic amblyopia: one-year results of a randomized crossover trial. Ophthalmology 2011; 118:1501.</a></li><li><a class="nounderline abstract_t">Repka MX. Acupuncture for anisometropic amblyopia. J AAPOS 2011; 15:3.</a></li><li><a class="nounderline abstract_t">Holmes JM, Beck RW, Kraker RT, et al. Risk of amblyopia recurrence after cessation of treatment. J AAPOS 2004; 8:420.</a></li><li><a class="nounderline abstract_t">Magramm I. Amblyopia: etiology, detection, and treatment. Pediatr Rev 1992; 13:7.</a></li><li><a class="nounderline abstract_t">Mirabella G, Hay S, Wong AM. Deficits in perception of images of real-world scenes in patients with a history of amblyopia. Arch Ophthalmol 2011; 129:176.</a></li><li><a class="nounderline abstract_t">Grant S, Melmoth DR, Morgan MJ, Finlay AL. Prehension deficits in amblyopia. Invest Ophthalmol Vis Sci 2007; 48:1139.</a></li><li><a class="nounderline abstract_t">Webber AL, Wood JM, Gole GA, Brown B. The effect of amblyopia on fine motor skills in children. Invest Ophthalmol Vis Sci 2008; 49:594.</a></li><li><a class="nounderline abstract_t">Niechwiej-Szwedo E, Goltz HC, Chandrakumar M, et al. Effects of anisometropic amblyopia on visuomotor behavior, part 2: visually guided reaching. Invest Ophthalmol Vis Sci 2011; 52:795.</a></li><li><a class="nounderline abstract_t">Packwood EA, Cruz OA, Rychwalski PJ, Keech RV. The psychosocial effects of amblyopia study. J AAPOS 1999; 3:15.</a></li><li><a class="nounderline abstract_t">Wen G, McKean-Cowdin R, Varma R, et al. General health-related quality of life in preschool children with strabismus or amblyopia. Ophthalmology 2011; 118:574.</a></li><li><a class="nounderline abstract_t">Rahi JS, Cumberland PM, Peckham CS. Does amblyopia affect educational, health, and social outcomes? Findings from 1958 British birth cohort. BMJ 2006; 332:820.</a></li></ol></div><div id="topicVersionRevision">Topic 104837 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Day S. Normal and abnormal visual development. In: Pediatric Ophthalmology, Taylor D (Ed), Blackwell Scientific Publications, Cambridge, MA 1990. p.7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.aao.org/preferred-practice-pattern/amblyopia-ppp--september-2012" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Academy of Ophtalmology Pediatric Ophthalmology/Strabismus Panel. Preferred Practice Pattern Guidelines. Amblyopia. American Academy of Ophthalmology, San Francisco, CA: American Academy of Ophthalmology; 2012. Available at: http://www.aao.org/preferred-practice-pattern/amblyopia-ppp--september-2012 (Accessed on August 05, 2015).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24789375" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460000" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The sensitive period for strabismic amblyopia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216059" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Natural history of amblyopia untreated owing to lack of compliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710809" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21746970" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of age on response to amblyopia treatment in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360300" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055546" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The sensitive period: transfer of fixation after occlusion for strabismic amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824215" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Randomized trial of treatment of amblyopia in children aged 7 to 17 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751032" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of anisometropic amblyopia in children with refractive correction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548811" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Refractive adaptation in amblyopia: quantification of effect and implications for practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21959371" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Optical treatment of strabismic and combined strabismic-anisometropic amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513928" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interventions for unilateral and bilateral refractive amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837378" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of occlusion for strabismic amblyopia: can an optimal duration be identified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675864" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 1999 Costenbader Lecture. Outcome study in amblyopia: treatment and practice pattern variations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613577" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Optical penalization can improve vision after occlusion treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9400778" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25051925" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Interventions for strabismic amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15838439" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23755872" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A randomized trial of increasing patching for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25695355" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Time course and predictors of amblyopia improvement with 2 hours of daily patching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751033" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9972510" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Outcome of occlusion treatment for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703134" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The therapy of amblyopia: an analysis comparing the results of amblyopia therapy utilizing two pooled data sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597512" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516801" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The course of moderate amblyopia treated with patching in children: experience of the amblyopia treatment study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742836" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized trial of patching regimens for treatment of moderate amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855283" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Objectively monitored patching regimens for treatment of amblyopia: randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1995038" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Anisometropic and strabismic amblyopia in the age group 2 years and above: a prospective study of the results of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752199" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Compliance and results of treatment for amblyopia in children more than 8 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084751" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomised controlled trial of written information: the effect on parental non-concordance with occlusion therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920669" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An educational cartoon accelerates amblyopia therapy and improves compliance, especially among children of immigrants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26614629" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Assessing interventions to increase compliance to patching treatment in children with amblyopia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35129211" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35938643" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of Dichoptic Therapy Versus Occlusion Therapy in Children With Anisometropic Amblyopia: A Prospective Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36306974" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : An Eye-Tracking-Based Dichoptic Home Treatment for Amblyopia: A Multicenter Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27832248" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Binocular iPad Game vs Patching for Treatment of Amblyopia in Children: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222336" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intensive occlusion therapy for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625933" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sutured protective occluder for severe amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195233" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Glued patches for children resistant to amblyopia occlusion therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3681611" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Severe visual loss resulting from occlusion therapy for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879129" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135409" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Atropine penalisation versus occlusion as the primary treatment for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064841" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821369" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Conventional occlusion versus pharmacologic penalization for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18695096" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15522375" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A randomized trial of atropine regimens for treatment of moderate amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976946" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Further validation of the Amblyopia Treatment Index parental questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21035063" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluating the burden of amblyopia treatment from the parent and child's perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824233" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of amblyopia in older children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149161" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Stability of visual acuity after the cessation of amblyopia treatment: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25727586" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A randomized trial of adding a plano lens to atropine for amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20210280" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Termination of amblyopia treatment: when to stop follow-up visits and risk factors for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363058" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Factors associated with recurrence of amblyopia on cessation of patching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804358" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The method of treatment cessation and recurrence rate of amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360207" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term outcomes of photorefractive keratectomy for anisometropic amblyopia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16935239" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Refractive surgery for high bilateral myopia in children with neurobehavioral disorders: 2. Laser-assisted subepithelial keratectomy (LASEK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17604197" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Facilitation of amblyopia management by laser in situ keratomileusis in high anisometropic hyperopic and myopic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18053899" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Laser-assisted subepithelial keratectomy for anisometropic amblyopia in children: outcomes at 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25499167" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Whole-population vision screening in children aged 4-5 years to detect amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767138" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Amblyopia: could we do better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12241931" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18207121" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparative efficacy of penalization methods in moderate to mild amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19139333" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacological plus optical penalization treatment for amblyopia: results of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061262" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The possible role of retinal dopaminergic system in visual performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22653761" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and tolerance of levodopa to treat amblyopia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676904" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A randomized trial of levodopa as treatment for residual amblyopia in older children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7622080" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of citicoline on visual acuity in amblyopia: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9550353" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cytidin-5'-diphosphocholine enhances the effect of part-time occlusion in amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25727578" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Binocular iPad treatment for amblyopia in preschool children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25611129" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Binocular iPad treatment of amblyopia for lasting improvement of visual acuity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25060850" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A binocular iPad treatment for amblyopic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25060850" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A binocular iPad treatment for amblyopic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149771" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Randomized controlled trial of patching vs acupuncture for anisometropic amblyopia in children aged 7 to 12 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459451" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adjunctive effect of acupuncture to refractive correction on anisometropic amblyopia: one-year results of a randomized crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397797" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Acupuncture for anisometropic amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492733" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Risk of amblyopia recurrence after cessation of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734442" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Amblyopia: etiology, detection, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320963" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Deficits in perception of images of real-world scenes in patients with a history of amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325157" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prehension deficits in amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18235004" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The effect of amblyopia on fine motor skills in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051723" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effects of anisometropic amblyopia on visuomotor behavior, part 2: visually guided reaching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071896" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The psychosocial effects of amblyopia study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20884059" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : General health-related quality of life in preschool children with strabismus or amblyopia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16520328" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Does amblyopia affect educational, health, and social outcomes? Findings from 1958 British birth cohort.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
